CUSIP 697947109 · who reports it, how much, and how much it matters to them
19 of the 720 hedge fund managers we track reported shares of Palvella Therapeutics, Inc. (Nasdaq: PVLA) on Form 13F for 30 June 2026. Between them they reported USD 270m. The largest position belongs to Suvretta Capital Management, at USD 174m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management4 funds on PPLI.com | USD 174m | 3.2% |
| 2 | Orbimed Advisors1 fund on PPLI.com | USD 45m | 0.8% |
| 3 | Awm Investment Company6 funds on PPLI.com | USD 11m | 0.9% |
| 4 | Renaissance Technologies13 funds on PPLI.com | USD 8.1m | 0.0% |
| 5 | Millennium Management6 funds on PPLI.com | USD 8m | 0.0% |
| 6 | Balyasny Asset Management25 funds on PPLI.com | USD 6.8m | 0.0% |
| 7 | Apis Capital Advisors4 funds on PPLI.com | USD 6m | 0.6% |
| 8 | Adage Capital Management1 fund on PPLI.com | USD 3.8m | 0.0% |
| 9 | Capricorn Fund Managers8 funds on PPLI.com | USD 2.2m | 0.2% |
| 10 | Two Sigma Investments35 funds on PPLI.com | USD 1.9m | 0.0% |
| 11 | Tudor Investment Corporation10 funds on PPLI.com | USD 1.2m | 0.0% |
| 12 | Exoduspoint Capital Management7 funds on PPLI.com | USD 840,000 | 0.0% |
| 13 | Squarepoint Ops7 funds on PPLI.com | USD 791,000 | 0.0% |
| 14 | Citadel Advisors32 funds on PPLI.com | USD 538,000 | 0.0% |
| 15 | Marshall Wace LLP84 funds on PPLI.com | USD 436,000 | 0.0% |
| 16 | Brevan Howard Capital Management39 funds on PPLI.com | USD 333,000 | 0.0% |
| 17 | Fulcrum Asset Management LLP7 funds on PPLI.com | USD 174,000 | 0.0% |
| 18 | Bayforest Capital1 fund on PPLI.com | USD 31,787 | 0.0% |
| 19 | The Quarry1 fund on PPLI.com | USD 3,515 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Suvretta Capital Management | USD 174m | 3.2% |
| 2 | Awm Investment Company | USD 11m | 0.9% |
| 3 | Orbimed Advisors | USD 45m | 0.8% |
| 4 | Apis Capital Advisors | USD 6m | 0.6% |
| 5 | Capricorn Fund Managers | USD 2.2m | 0.2% |
| 6 | Bayforest Capital | USD 31,787 | 0.0% |
| 7 | Fulcrum Asset Management LLP | USD 174,000 | 0.0% |
| 8 | Renaissance Technologies | USD 8.1m | 0.0% |
| 9 | Balyasny Asset Management | USD 6.8m | 0.0% |
| 10 | Adage Capital Management | USD 3.8m | 0.0% |
Palvella Therapeutics, Inc. trades under the symbol PVLA on the Nasdaq. Its CUSIP, the code used on Form 13F, is 697947109.
19 of the 720 hedge fund managers PPLI.com tracks reported Palvella Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Suvretta Capital Management (USD 174m), Orbimed Advisors (USD 45m), Awm Investment Company (USD 11m), Renaissance Technologies (USD 8.1m) and Millennium Management (USD 8m).
19 managers in our coverage reported it, and between them they run 291 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Suvretta Capital Management, where the position was 3.2% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Palvella Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.